Histamine-induced inhibition of leukotriene biosynthesis in human neutrophils: involvement of the H2 receptor and cAMP.
1. Histamine is generally regarded as a pro-inflammatory mediator in diseases such as allergy and asthma. A growing number of studies, however, suggest that this autacoid is also involved in the downregulation of human polymorphonuclear leukocyte (PMN) functions and inflammatory responses through activation of the Gs-coupled histamine H(2) receptor. 2. We report here that histamine inhibits thapsigargin- and ligand (PAF and fMLP)-induced leukotriene (LT) biosynthesis in human PMN in a dose-dependent manner. 3. The suppressive effect of histamine on LT biosynthesis was abrogated by the histamine H(2) receptor antagonists cimetidine, ranitidine, and tiotidine. In contrast, the histamine H(1), H(3), and H(4) receptor antagonists used in this study were ineffective in counteracting the inhibitory effect of histamine on the biosynthesis of LT in activated human PMN. 4. The inhibition of LT biosynthesis by histamine was characterized by decreased arachidonic acid release and 5-lipoxygenase translocation to the nuclear membrane. 5. Incubation of PMN with the cAMP-dependent protein kinase (PKA) inhibitor N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline-sulfonamide prevented the inhibitory effect of histamine on LT biosynthesis, suggesting an important role for PKA in this effect of histamine on LT biosynthesis in PMN. 6. These data provide the first evidences that, similarly to adenosine and prostaglandin E(2), histamine is a potent suppressor of LT biosynthesis, and support the concept that histamine may play a dual role in the regulation of inflammation.
Flamand
Nicolas
N
Centre de Recherche en Rhumatologie et Immunologie, Centre de Recherche du CHUQ and Faculté de Médecine, CHUL, Office T1-49, 2705 Laurier, Sainte-Foy, Université Laval, Québec, Canada G1V 4G2.
Plante
Hendrick
H
Picard
Serge
S
Laviolette
Michel
M
Borgeat
Pierre
P
D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D016718:Arachidonic Acid / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D000242:Cyclic AMP / Q000502:physiology*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006632:Histamine / Q000494:pharmacology*; D017442:Histamine Agonists / Q000494:pharmacology; D006633:Histamine Antagonists / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology; D007975:Leukotriene B4 / Q000096:biosynthesis; D015289:Leukotrienes / Q000096:biosynthesis*; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D009685:Nuclear Envelope / Q000187:drug effects / Q000201:enzymology; D010741:Phospholipases A / Q000378:metabolism; D011970:Receptors, Histamine H2 / Q000378:metabolism*; D013268:Stimulation, Chemical; D013449:Sulfonamides; D014178:Translocation, Genetic / Q000235:genetics
D004791:Enzyme Inhibitors; D017442:Histamine Agonists; D006633:Histamine Antagonists; D007546:Isoquinolines; D015289:Leukotrienes; D011970:Receptors, Histamine H2; D013449:Sulfonamides; D007975:Leukotriene B4; D016718:Arachidonic Acid; D006632:Histamine; D000242:Cyclic AMP; D001094:Arachidonate 5-Lipoxygenase; D017868:Cyclic AMP-Dependent Protein Kinases; D010741:Phospholipases A; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; D002118:Calcium